World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 5, Number 3, June 2014, pages 118-125

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma

**Table 1.** Response Definitions
Complete response (CR)	Disappearance of all contrast-enhancing tumor.
Partial response (PR)	50% or more reduction in the size of measurable disease.
Disease progression (DP)	25% or more increase in the size of measurable disease.
Stable disease (SD)	All other situations.

Table 1. Response Definitions

Complete response (CR)

Disappearance of all contrast-enhancing tumor.

Partial response (PR)

50% or more reduction in the size of measurable disease.

Disease progression (DP)

25% or more increase in the size of measurable disease.

Stable disease (SD)

All other situations.

**Table 2.** Dose Modification Based on Hematological and Renal Function Results
Hematology
For day 1
Neutrophils (10³/mL)		Platelets (10³/mL)	Dose
≥ 1.5	and	> 100	100%
< 1.5	or	< 100	Delay
Renal function test
Creatinine	Dose
< 2 upper normal limit	100%
≥ 2 upper normal limit	Delay
Liver function tests
Bilirubin (µmol/L)		ALT, AST	Dose
≤ 25	and	≤ 2.5 upper normal limit	100%
> 25	or	> 2.5 upper normal limit	Delay

Table 2. Dose Modification Based on Hematological and Renal Function Results

Hematology

For day 1

Neutrophils (10³/mL)

Platelets (10³/mL)

Dose

≥ 1.5

and

> 100

100%

< 1.5

< 100

Delay

Renal function test

Creatinine

Dose

< 2 upper normal limit

100%

≥ 2 upper normal limit

Delay

Liver function tests

Bilirubin (µmol/L)

ALT, AST

Dose

≤ 25

and

≤ 2.5 upper normal limit

100%

> 25

> 2.5 upper normal limit

Delay

**Table 3.** Patients’ and Disease’s Characteristics of the Current Study
Characteristics	Details	Patients No.	Percentage (%)
Age	18 - 20	6	30
	> 20 - 40	11	55
	> 40 - 60	3	15
	> 60	0	0
Sex	Male	15	75
	Female	5	25
Performance status	100	3	6.7
	90	9	23.3
	80	8	43.3
	70	0	23.3
	60	0	3.3
Pathology	LGG	18	90
	Ependymoma	2	10
Site of recurrence	Temporal lobe	13	65
	Parietal lobe	6	30
	Cerebellar	1	5
Pretreatment tumor size	1 - 2 cm	9	45
	2 - 4 cm	11	55
	> 5 cm	0	0

Table 3. Patients’ and Disease’s Characteristics of the Current Study

Characteristics

Details

Patients No.

Percentage (%)

Age

18 - 20

> 20 - 40

> 40 - 60

> 60

Sex

Male

Female

Performance status

100

6.7

23.3

43.3

23.3

3.3

Pathology

LGG

Ependymoma

Site of recurrence

Temporal lobe

Parietal lobe

Cerebellar

Pretreatment tumor size

1 - 2 cm

2 - 4 cm

> 5 cm

**Table 4.** Characters of the Eight Patients Who Achieved Objective Responses
Patient number	Response achieved	Age	Sex	PS	Pathology type	Time interval
1	CR	27	male	100	LGG	15
2	CR	20	male	90	LGG	17
3	PR	18	female	90	LGG	12
4	PR	18	male	100	LGG	15
5	PR	18	male	90	Ependymoma	13
6	PR	31	male	90	LGG	16
7	PR	19	female	100	LGG	17
8	PR	32	male	90	LGG	12

Table 4. Characters of the Eight Patients Who Achieved Objective Responses

Patient number

Response achieved

Age

Sex

Pathology type

Time interval

male

100

LGG

male

LGG

female

LGG

male

100

LGG

male

Ependymoma

male

LGG

female

100

LGG

male

LGG

**Table 5.** The 12-Month OS for Treatment Group Grouped by Prognostic Factors
12-month OS	Number (%)	P value
Age
< 40 years old	16 (94%)	0.001
> 40 years old	1 (33%)	0.001
Performance status
100-90	11 (91%)	0.6
80	6 (75%)	0.6
Tumor size
< 2 cm	8 (89%)	0.03
> 2 cm	9 (81%)	0.03
Time interval between the two RT courses
8 - 12 months	5 (71%)	0.001
12 - 16 months	11 (91%)	0.001
16 - 18 months	1 (100%)	0.001

Table 5. The 12-Month OS for Treatment Group Grouped by Prognostic Factors

12-month OS

Number (%)

P value

Age

< 40 years old

16 (94%)

0.001

> 40 years old

1 (33%)

0.001

Performance status

100-90

11 (91%)

0.6

6 (75%)

0.6

Tumor size

< 2 cm

8 (89%)

0.03

> 2 cm

9 (81%)

0.03

Time interval between the two RT courses

8 - 12 months

5 (71%)

0.001

12 - 16 months

11 (91%)

0.001

16 - 18 months

1 (100%)

0.001